Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
FS KKR Capital Corp reported third quarter 2026 net investment income of $0.46 per share and a net asset value of $18.28 per share. The company also highlighted the repurchase of approximately 6 million shares for $69 million during the quarter and declared a regular distribution of $0.44 per share plus a special distribution of $0.20 per share.
“During the third quarter, FSK continued making progress toward our previously stated strategic goals. During the quarter we repurchased approximately six million shares of common stock at a weighted average price of $11.24 per share, totaling approximately $69 million. In addition, we received full and partial repayments of portfolio investments totaling $442 million. As our investment team continues focusing on portfolio rotation, we expect our portfolio will move toward more first lien exposure.”
Michael C. Forman, Chief Executive Officer and Chairman
Zai Lab reported third quarter 2026 total revenues of $108.2 million, representing a 2% sequential increase in net product revenue. The company highlighted positive clinical data for its internally developed ADC, zocilurtatug pelitecan (zoci), in small cell lung cancer and expects 2027 to be a pivotal year with its first potential U.S. BLA submission.
Term
Q3 2026
“We are approaching a defining period for Zai Lab, as we advance toward bringing our first internally developed innovative medicines to patients globally. The strong first-line combination data for zocilurtatug pelitecan (zoci) presented at ESMO strengthen our confidence in its potential to become an ADC backbone of choice in small cell lung cancer.”
Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab
“This profile supports taking a standard chemotherapy-free regimen into a global Phase 3 study and gives us a strong foundation to build on with T-cell engager combinations. Our registrational programs in SCLC and neuroendocrine carcinomas are advancing toward readouts that could support our first U.S. BLA submission in 2027.”
Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab
Americold Realty Trust reported Q3 2026 financial results with total revenues of $691.6 million, a 4.2% increase year-over-year. The company recognized a significant one-time gain from the formation of a joint venture with EQT, which allowed for a $1.15 billion reduction in outstanding debt and a strengthened balance sheet.
“A combination of best-in-class execution and continued industry stabilization allowed us to deliver another strong quarter of operating and financial performance. Ongoing gains in occupancy, throughput and pricing, along with lower SG&A from our cost savings initiatives, contributed to year-over-year growth in revenue and NOI as well as AFFO of $0.35 per share for the quarter.”
Rob Chambers, CEO of Americold
“A significant achievement during the quarter was the closing of our joint venture with EQT. The transaction enabled us to reduce our outstanding debt by $1.15 billion, reducing net leverage ratio by a full turn and significantly strengthening our balance sheet and financial flexibility.”
Strategic Education, Inc. reported Q3 2026 revenue of $325.1 million, up 1.6% year-over-year, driven by growth in its Education Technology Services segment. The company recorded a $134.1 million non-cash impairment charge related to its Australia and New Zealand operations due to international student immigration constraints, resulting in a net loss of $98.3 million. Adjusted diluted EPS on a constant currency basis increased to $1.69 from $1.63 in the prior year.
NCR Voyix reported total revenue of $539 million for the third quarter of 2026, a decrease from $677 million in the prior year, primarily due to a significant drop in product revenue. Despite the revenue decline, the company achieved a net income of $24 million compared to a net loss of $19 million in the same period last year, driven by improved operating margins and income from discontinued operations.
Molson Coors Beverage Company reported Q3 2026 financial results, with net sales decreasing 1.6% to $2.93 billion. While U.S. GAAP net income improved significantly compared to a prior-year loss that included a massive impairment charge, underlying income before taxes fell 17.4% in constant currency due to external headwinds.
Term
Q3 2026
“Since launching Horizon 2030 earlier this year, we've been laying important groundwork for long-term success by building the portfolio, capabilities, routines, and operating discipline needed to perform more consistently across the business. We've taken decisive actions intended to strengthen our share trend performance, accelerate our portfolio transformation, simplify our cost structure, and return cash to shareholders. We believe our strategy is on the right track, but these outcomes are not yet scaled enough to offset the headwinds that we experienced in the third quarter.”
Rahul Goyal, President and Chief Executive Officer
“Our third quarter financial results reflect both the benefits of the deliberate actions we've taken under Horizon 2030 and the impact of external headwinds that intensified as the year progressed. Those pressures weighed on our performance in the quarter and are likely to remain a factor in the near term. At the same time, we are seeing progress from the actions we are taking, and the challenging environment does not change our confidence in our long-term strategy.”
Kimberly-Clark reported third quarter 2026 net sales of $4.1 billion, down 0.4%, with organic sales declining 1.3% due to social media disruptions in China and inventory movements in North America. Adjusted EPS from continuing operations rose 17.2% to $1.70, while the company highlighted the completion of its Kenvue transaction as a defining strategic milestone.
Term
Q3 2026
“The completion of our Kenvue transaction earlier this week marks a defining moment in the 154 year history of Kimberly-Clark. We embark on an exciting next chapter focused on delivering better care, in more hands, and enabling smarter health.”
Mike Hsu, Kimberly-Clark Chairman and CEO
“Our third quarter results reflect a dynamic operating environment and several discrete impacts. Our team continues to execute with agility, and the underlying momentum of our business remains strong.”
Agios Pharmaceuticals reported Q3 2026 financial results, highlighted by record quarterly net product revenue of $55.4 million, a four-fold increase year-over-year driven by the U.S. launch of AQVESME in thalassemia. The company ended the quarter with $907 million in cash and is preparing for a potential February 2027 FDA approval of mitapivat in sickle cell disease.
Term
Q3 2026
“The third quarter was a record for our product revenue, outperforming our entire 2025 total in just three months. This growth was driven by the U.S. commercial launch of AQVESME in thalassemia, where broadening demand is translating into a durable base of patients on therapy.”
Brian Goff, Chief Executive Officer
“This launch has built the commercial foundation for our largest indication opportunity with mitapivat – sickle cell disease. Our conviction in mitapivat for patients with sickle cell disease is grounded in the robust efficacy and safety data generated to date and we are launch-ready ahead of our PDUFA goal date of February 1, 2027.”
United Parks & Resorts reported third quarter 2026 results with total revenue of $506.5 million and net income of $80.0 million, both down slightly year-over-year due to unfavorable weather and international headwinds. Despite a 4.7% decline in attendance, the company achieved record in-park per capita spending of $37.39 and reported an 8% increase in total pass sales.
Term
Q3 2026
“We are pleased with the underlying performance of our business, despite significantly unfavorable weather, calendar impacts and international headwinds during the quarter. Excluding the impact of these unusual headwinds, which amounted to approximately 325,000 visits, our attendance would have been up.”
Marc Swanson, CEO of United Parks & Resorts Inc.
“Looking ahead to 2027 and beyond, we see a clear path to deliver significantly higher attendance, revenue, Adjusted EBITDA and free cash flow.”
NCR Voyix reported third quarter 2026 financial results with revenue of $539 million, reflecting the impact of its hardware business transition. The company reported net income from continuing operations of $14 million and maintained its full-year 2026 outlook, though it now expects revenue to be at the lower end of its previously stated range.
“Our third quarter results were in line with our expectations, with our strong customer signings reflecting increasing demand for our Voyix Commerce Platform applications. The growth in remaining contract value, coupled with the progress we have made in scaling our deployments, reinforces our confidence in the opportunity ahead.”
James G. Kelly, Chief Executive Officer of NCR Voyix
Perimeter Group reported Q3 2026 financial results with net sales increasing 24% to $389.9 million and net income of $304.5 million. The company also completed its corporate name change from Perimeter Solutions, Inc. and integrated the $117.1 million acquisition of Monaco Enterprises.
InfuSystem Holdings reported Q3 2026 net revenues of $37.6 million, a 3% increase year-over-year, driven by strong growth in Oncology and Wound Care. Net income rose to $3.2 million, or $0.15 per diluted share, while Adjusted EBITDA margin expanded to 24.9%. The company reaffirmed its full-year 2026 guidance, expecting pro-forma revenue growth of 6% to 8%.
Term
Q3 2026
“We delivered another strong quarter, achieving record revenue of $37.6 million. After adjusting for the impact of the previously announced GE Healthcare contract restructuring, pro-forma revenue increased 10.2% compared to the prior-year period. Pro-forma growth has accelerated each quarter this year, up from 1.7% in the first quarter and 7.5% in the second quarter. We also increased Adjusted EBITDA by 12.5% and expanded Adjusted EBITDA margin to 24.9% from 22.8% in the prior-year period. These results reflect continued execution of our profitable growth strategy across our diversified operating platform.”
Carrie Lachance, Chief Executive Officer
“Growth during the quarter was driven by Oncology, where revenue grew 7.2%, and exceptional performance in Wound Care. Wound Care revenue increased $2.0 million, or 112%, compared to the prior-year period, including approximately $1.6 million of growth from our compression therapy product lines focused on lymphedema treatment.”
Evommune Licensing Deal with Hinova Pharmaceuticals Inc.
Evommune announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals for EVO570, an oral VAV1-directed molecular glue degrader. Evommune acquired worldwide rights (excluding Greater China) to develop, manufacture, and commercialize the candidate, which it plans to develop for rheumatoid arthritis.
Becton, Dickinson and Company (BD) reported Q4 fiscal 2026 revenue of $5.3 billion, a 5.4% increase, and full-year revenue of $19.5 billion. The company highlighted the completion of its transformation into a more focused MedTech company following the separation of its Life Sciences business and issued guidance for fiscal 2027.
“We delivered a strong fourth quarter, with 5.6% revenue growth and broad-based performance led by our key growth platforms. Fiscal 2026 was a defining year as we completed BD's transformation to a more focused MedTech company with separation of our Life Sciences business. We strengthened our core growth and expanded BD Excellence to elevate our commercial capabilities, accelerate innovation and drive greater productivity. We enter fiscal 2027 from a position of strength, with a portfolio built for durable performance and confidence in the long-term growth, earnings and cash-flow potential of New BD.”
Advance Auto Parts reported Q3 2026 net sales of $2.01 billion, a 1.2% decrease in comparable store sales. Despite a volatile demand environment, the company delivered an adjusted operating margin of 4.5% and raised its full-year free cash flow guidance to approximately $150 million.
Term
Q3 2026
“Our comparable sales performance improved as the quarter progressed. Main Street Pro outperformed throughout the quarter while DIY trends improved compared to the softer trends experienced during the summer. I thank the team for their hard work and commitment to serving our customers.”
Shane O'Kelly, president and chief executive officer
“Sales declined in the low-single-digit range during the first eight weeks before turning positive in the final four weeks, supported by improved transaction volumes. The Pro channel led performance in Q3, with low-single-digit sales growth including stronger Main Street Pro growth.”
Shane O'Kelly, president and chief executive officer
Sunshine Silver Mining & Refining completed its 50,000-meter infill drill program at the Sunshine Mine in Idaho, reporting high-grade silver results exceeding 1,000 gpt across multiple veins. The data will support an updated Mineral Resource Estimate in Q1 2027 and a Feasibility Study in Q2 2027 as the company targets a return to production in late 2028.
LeMaitre Vascular reported net sales of $68.0 million for Q3 2026, a 11% increase over the prior year, though net income decreased to $15.0 million from $17.4 million. For the nine months ended September 30, 2026, the company saw improved profitability with net income rising to $47.8 million compared to $42.2 million in the same period of 2025.
Graham Corp reported second quarter fiscal 2027 results with net sales increasing 6% to $69.8 million and net income rising 50% to $4.6 million. The company achieved a record backlog of $561.3 million and reaffirmed its full-year fiscal 2027 guidance for sales and adjusted EBITDA.
Term
Q2 2027
“Our second quarter results reflect strong execution across the business, highlighted by growth in Defense and Space, significant margin expansion and continued momentum across our end markets. Our record backlog of $561 million provides strong visibility into future growth and reinforces our confidence in the long-term opportunities ahead.”
Matthew J. Malone, President and Chief Executive Officer
“We are very pleased with the progress of FlackTek’s integration and the continued execution of our strategic initiatives, including the successful completion of our first customer test at our new cryogenic testing facility and the groundbreaking of our new facility in Arvada.”
Matthew J. Malone, President and Chief Executive Officer
Aspen Aerogels reported Q3 2026 revenue of $85.2 million, a 71% increase quarter-over-quarter, driven by growth in both Thermal Barrier and Energy Industrial segments. The company reported a net loss of $10.4 million, which included $15.1 million in costs related to an incident at its East Providence facility, while Adjusted EBITDA reached $19.8 million. Additionally, the company appointed Stacy D. Nieuwoudt to its Board of Directors, increasing the board size to seven members.
The GEO Group reported record-breaking third quarter 2026 results with revenues increasing 12% to $761.1 million and Adjusted EBITDA rising 21% to $145.3 million. The company updated its full-year 2026 guidance, including a significant increase in net income expectations following the $950 million sale of its Adelanto, California ICE Complex.
“Our diversified business units have continued to deliver strong financial and operational performance throughout 2026, and our third quarter 2026 results marked a record-breaking quarter for GEO, with the highest level of quarterly revenues and adjusted EBITDA ever reported in our company’s history.”
George C. Zoley, GEO’s Chairman, Chief Executive Officer and Founder
“Given the intrinsic value of our assets, including 48,000 owned beds; our strong financial performance in providing diversified secure support services; and our expected future growth, we believe that our stock continues to be significantly undervalued and that share repurchases are therefore a paramount capital allocation priority for our Company.”
George C. Zoley, GEO’s Chairman, Chief Executive Officer and Founder
Planet Fitness reported Q3 2026 financial results with total revenue increasing 9% to $360.0 million and system-wide same club sales growth of 1.5%. The company also announced a new $500 million share repurchase authorization and its entry into the Portuguese market through the acquisition of Be-Fit.
Term
Q3 2026
“We delivered same club sales growth ahead of our expectations and adjusted EBITDA margins of approximately 41% while making meaningful progress on the initiatives designed to accelerate member growth, reinforce affordability, and generate long-term value during the third quarter.”
Colleen Keating, Chief Executive Officer
“We are also energized by the international expansion opportunities available to us, most recently our acquisition of Be-Fit in Portugal, which marks our entry into a sixth international market and our second country in Europe.”
For the three months ended September 30, 2026, Regis Corp reported total revenue of $54.3 million, a decrease from $59.0 million in the prior year period. Net income for the quarter was $0.5 million, or $0.21 per basic share, compared to $1.4 million, or $0.56 per basic share, in the same period of 2025.
Regis Corporation reported financial results for its first fiscal quarter of 2027, achieving operating income of $5.3 million and consolidated same-store sales growth of 0.2%. The company generated positive cash from operations for the eighth consecutive quarter and repaid approximately $7.9 million of debt. Management noted that after reviewing refinancing alternatives, they intend to return to the debt markets in early calendar 2027 to take advantage of lower call premiums.
Term
Q1 2027
“In the first fiscal quarter, we achieved operating income of $5.3 million, Adjusted EBITDA of $7.7 million, and generated positive cash from operations, reinforcing a solid foundation for improving performance across our business. Supercuts delivered a 2.0% increase in same-store sales, contributing to modest overall growth across the Regis portfolio. At the same time, declining guest traffic in our company-owned salons requires immediate attention. We are taking targeted actions to increase traffic across our brands and build a stronger business that delivers sustainable growth and long-term value for our shareholders.”
Susan Lintonsmith, Regis Corporation’s President and Chief Executive Officer
“During the first quarter, we repaid approximately $7.9 million of debt and ended the quarter with $20.8 million in cash. We recently completed a comprehensive review of refinancing alternatives with active oversight from our Board, and working closely with our newest director, who is a significant shareholder. We evaluated a range of options including senior bank debt, private credit financing, preferred equity structures, and whole business securitization. Based on the feedback we received, we determined that refinancing now would not deliver sufficient value to shareholders, given the scheduled decline in the call premium on our existing debt in mid-2027.”
Kersten Zupfer, Regis Corporation’s Executive Vice President and Chief Financial Officer
FS KKR Capital Corp reported a net decrease in net assets resulting from operations of $404 million for the nine months ended September 30, 2026, compared to a $125 million increase in the prior year period. The company's net asset value per share declined to $18.28 from $20.89 at the end of 2025, primarily driven by net realized and unrealized losses on investments.
Enovis Corporation reported net sales of $558.7 million for the third quarter of 2026, a slight increase from $548.9 million in the prior year. The company achieved a net income of $3.4 million for the quarter, a significant recovery from a net loss of $570.9 million in Q3 2025, which was primarily driven by a $548.4 million goodwill impairment charge.
NexPoint Real Estate Finance reported Q3 2026 financial results with a net loss of $12.2 million and cash available for distribution of $14.0 million. The company maintained a $1.0 billion investment portfolio focused on life sciences and multifamily sectors and provided Q4 2026 earnings guidance.
Term
Q3 2026
“Our third quarter results reflect the consistency of the strategy we’ve outlined for investors: earnings that covered our dividend and a portfolio focused on sectors with durable demand. While many lenders continue to work through legacy credit issues, our disciplined underwriting allows us to stay selective and deploy capital where we see the best risk-adjusted opportunities, supporting stable income, portfolio growth, and long-term value for our shareholders.”
Trulieve reported a net loss of $403.0 million for the nine months ended September 30, 2026, primarily driven by a $403.3 million loss on a Deconsolidation Transaction. Revenue for the nine-month period decreased to $787.9 million from $888.0 million in the prior year, while cash and cash equivalents increased to $326.7 million.
Air Products reported fiscal year 2026 results with sales of $13.0 billion, an 8% increase over the prior year, and adjusted EPS of $13.45, up 12%. The company provided fiscal 2027 adjusted EPS guidance of $14.15 to $14.50 and expects capital expenditures between $3.0 billion and $3.5 billion.
The Cigna Group reported third quarter 2026 total revenues of $73.7 billion, a 6% increase year-over-year, driven by growth in Evernorth Health Services and Cigna Healthcare. The company raised its full-year 2026 outlook for adjusted income from operations to at least $30.60 per share and announced a multi-year $3 billion modernization initiative called 'Accelerate to One'.
Term
3 months
“Our vision for The Cigna Group’s next chapter of profitable growth is grounded in delivering greater value and personalized experiences for our customers, with three priorities: driving core growth, leveraging our distinct capabilities, and executing with discipline. As we put our strategy in action, our strong third quarter results demonstrate how we are building on this momentum by making health care more affordable and personalized, while advancing Accelerate to One to drive productivity, reduce costs, and support sustained long-term earnings growth.”
Brian Evanko, President and Chief Executive Officer of The Cigna Group
Trulieve Cannabis Corp. reported Q3 2026 revenue of $230 million and positive net income of $1 million, marking a significant period following its uplisting to the NYSE. The company highlighted major regulatory milestones, including receiving final DEA registrations for medical marijuana dispensaries and the removal of 280E tax burdens.
“State licensed medical marijuana rescheduling unlocked major milestones including DEA registration, removal of 280E tax, and uplisting to the NYSE. Third quarter results demonstrate the strength of our medical cannabis platform underscored by revenue, margins, and cash generation. With meaningful growth expansion opportunities in Georgia and Texas, we are in the early stages of an accelerated growth cycle.”